At present, the DC vaccine sipuleucel-T (consisting of autologous DCs pulsed with the recombinant fusion protein containing GM-CSF and prostatic acid phosphatase) has been approved for prostate cancer [185]. This evidence concerns the gene ACP3 and prostate cancer.